title: Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.
abstract: Neuroendocrine tumours of the gastroenteropancreatic system represent a therapeutic challenge. Current therapeutic strategies will be presented and discussed with especial consideration given to biotherapeutic regimens in metastatic tumour disease.
authors.affiliation: Department of Internal Medicine and Gastroenterology, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Faiss
authors.forename: H
authors.initials: H
authors.lastname: Scherübl
authors.forename: E O
authors.initials: EO
authors.lastname: Riecken
authors.forename: B
authors.initials: B
authors.lastname: Wiedenmann
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007370:Interferon Type I; D010456:Peptides, Cyclic; D011994:Recombinant Proteins; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide